

ANMI (BELGIUM) and Eczacıbaşı-Monrol signed an exclusive distribution agreement for the supply ANMI's products including PSMA-11 cold kits for diagnosis and management of prostate cancer in 48 countries.

Liège, Belgium and Istanbul, Turkey - September 29th 2015

ANMI and Eczacıbaşı-Monrol announced their collaboration for distribution of ANMI's products in 48 countries in Eastern Europe, Middle East and Asia. The first commercial product is PSMA-11 cold kit for production ^{68}Ga -PSMA-11, for diagnosis and management of prostate cancer. This is part of the common strategy of Eczacıbaşı-Monrol and ANMI to be able to provide a reliable, straight forward and cost effective processes for ^{68}Ga tracers production and in particular PSMA-11.

Ludovic Wouters, CEO and Co-founder of ANMI commented, "Eczacıbaşı-Monrol is an example of a strong based company in nuclear products pharmaceuticals. Their position on the market and recent acquisitions show a real will to be a driver in the radiopharmaceutical field. It is a fantastic opportunity for ANMI to collaborate with a cutting-edge company such as Eczacıbaşı-Monrol".

With it's 300 employees and 15 distributors to supply nuclear medicine centers in Turkey and more than 40 countries around the world, Eczacıbaşı-Monrol is very excited to announce a collaboration with ANMI for the distribution of innovative solutions to facilitate the synthesis of theranostic radiopharmaceuticals for 48 countries in Eastern Europe, Middle East and Asia. With ANMI's premium quality products and services Eczacıbaşı-Monrol will have a stronger product portfolio for its customer.

About ANMI

ANMI SA is an Active Pharmaceutical Ingredients (API) supplier for radiometals labeled radiopharmaceuticals and a global service provider in the nuclear medicine field located in Liège, Belgium.

ANMI has developed innovative solutions to facilitate the synthesis of these theranostic radiopharmaceuticals and to ease their daily production in hospitals.

ANMI vision is focusing on increasing patient access to new highly specific theranostic radiopharmaceuticals through straight forward and cost effective production processes.

More information on www.anmi.be or info@anmi.be

About Eczacıbaşı-Monrol

Eczacıbaşı-Monrol Nuclear Products, an equal share joint venture between Monrol Nuclear Products Inc. and Eczacıbaşı Pharmaceuticals Manufacturing that was established in 2008, serves for the development nuclear medicine market through the production of high-quality radiopharmaceuticals for diagnosis and treatment. In addition to organic growth in Turkey and abroad, Eczacıbaşı-Monrol has expanded its operations and product portfolio through the acquisition of Mol-Image in 2011 and Capintec in 2012.

More information on www.monrol.com.tr